Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS)

• DOI: 10.1007/s00535-022-01851-1
• Publication Date: 2022-01-28T11:02:55Z
• Authors: Hiroshi Nakase; Yuki Hayashi; Daisuke Hirayama; Takayuki Matsumoto; Minoru Matsuura; Hideki Iijima; Katsuyoshi Matsuoka; Naoki Ohmiya; Shunji Ishihara; Fumihito Hirai; Daiki Abukawa; Tadakazu Hisamatsu; ; Makoto Sasaki; Masahiro Iizuka; Mikihiro Fujiya; Takayuki Matsumoto; Fukunori Kinjo; Shiro Nakamura; Noriko Kamata; Hideki Iijima; Yuri Etani; Fumiaki Ueno; Sakiko Hiraoka; Takeo Kondo; Takashi Kagaya; Makoto Naganuma; Kiyonori Kobayashi; Taku Kobayashi; Shuji Yamamoto; Yuji Naito; Tadakazu Hisamatsu; Yoki Furuta; Keichi Mitsuyama; Yu Hashimoto; Katsuhiro Arai; Shingo Kato; Itaru Iwama; Motohiro Esaki; Hiroki Tanaka; Hiroshi Nakase; Satoshi Motoya; Atsuo Maemoto; Tomofumi Ashida; Nobuaki Nishimata; Akira Andoh; Hironori Yamamoto; Shunji Ishihara; Toshiaki Shimizu; Yasuharu Maeda; Kenji Kinoshita; Katuyuki Fukuda; Jun Kato; Ken Takeuchi; Masakazu Nagahori; Masakatsu Fukuzawa; Masayuki Saruta; Michio Itabashi; Masaru Shinozaki; Soichiro Ishihara; Naoki Yoshimura; Katsuyoshi Matsuoka; Yoichi Kakuta; Kenichi Takahashi; Ryosuke Sakemi; Sohachi Nanjo; Shusaku Yoshikawa; Keiji Ozeki; Ayako Fuchigami; Takehiko Katsurada; Kenji Watanabe; Hirotake Sakuraba; Fumihito Hirai; Takashi Hisabe; Naoki Ohmiya; Ryota Hokari; Katsuhiko Nakai; Daiki Abukawa; Shojiro Yamamoto; Kazutaka Koganei; Reiko Kunisaki; Akira Hokama
• Keywords: Interim; Colorectal Surgery; Surgical oncology; Interim analysis; 2019-20 coronavirus outbreak

Abstract Background The spread of coronavirus disease 2019 (COVID-19) had a major impact on the health people worldwide. clinical background and course inflammatory bowel (IBD) among Japanese patients with COVID-19 remains unclear. Methods This study is an observational cohort IBD diagnosed COVID-19. Data age, sex, (classification, treatment, activity), symptoms severity, treatment were analyzed. Results From 72 participating facilities in Japan, 187 registered from June 2020 to October 2021. estimated incidence COVID19 was 0.61%. majority (73%) remission. According WHO classification regarding 93% (172/184) non-severe episodes, while 7% (12/184) severe cases including serious conditions. 90.9% (165/187) no change activity. A logistic regression analysis stepwise method revealed that older higher body mass index (BMI), steroid use independent risk factors for severity. Six nine who after vaccination receiving anti-tumor necrosis factor (TNF)-α antibodies. Conclusion Age, BMI associated severity patients.